{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Board Pearls","title":"Chapter 33, Ep 2 of 5: C. diff Recurrence Toolkit","html":"","width":"100%","height":180,"duration":534,"description":"Recurrence is the dominant management problem in C. diff, and this episode organizes the entire toolkit around a single mechanism: the spore. Surviving spores germinate once the antibiotic stops, so every tool either keeps colonic drug above the killing threshold across successive germination waves or restores the commensal community that denies spores a niche. The drug you reach for depends on what was used first, the structural taper-and-pulse pattern matters more than the molecule, and after two or more recurrences the strategy shifts from antibiotics to microbiome restoration. Bezlotoxumab and prophylaxis close the loop in the right patients.\n \nTopics covered\n\nThe spore-germination cycle behind recurrence\nFidaxomicin for a first recurrence\nExtended-pulse fidaxomicin dosing\nVancomycin tapered-pulsed dosing\nBezlotoxumab host-immunity layer\nMicrobiome restoration after multiple recurrences\nLive biotherapeutics Rebyota and Vowst\nOral vancomycin prophylaxis\n \nKey decisions\n\nAfter a first recurrence in a patient treated with vancomycin or metronidazole, switch to fidaxomicin, using extended-pulse dosing in older patients with a prior episode and coverage.\nAfter a first recurrence in a patient treated initially with fidaxomicin, use vancomycin tapered-pulsed dosing rather than repeating a flat ten-day course, because the temporal exposure pattern is what prevents recurrence.\nAdd bezlotoxumab ten milligrams per kilogram as a single infusion during the antibiotic course in patients with recurrence risk factors, and never substitute it for the antibiotic or use it as monotherapy.\nAfter two or more recurrences, shift from repeat antibiotics, which sustain only about thirty percent cure, to microbiome restoration, which reaches eighty to ninety percent sustained cure.\nGive the standardized live biotherapeutic products after a completed antibiotic course: rectal single-dose Rebyota or oral spore Vowst, endorsed by ACG for the second or subsequent recurrence.\nOffer oral...","thumbnail_url":"https://img.transistorcdn.com/-FuAdDBcPDLhEoUmroZKtOBRvuBn_FHPpYlh41hOnU4/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9iNzlh/ZTU4Y2MzNWExMjQ5/MjA5OWMwMmI3ZTk5/NGFiZS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}